Aalto Bio Reagents, a leading developer and provider of raw materials to the in-vitro diagnostics industry and to research laboratories globally, announced the availability of its Tri-Plex suite of proteins and antibodies which include its market leading Zika Virus(ZIKV) primary Envelope and NS1 proteins plus Chikungunya (CHIKV) E2 wildtype, E1 mutant and E1 wildtype proteins and a complete set of Dengue virus (DENV) proteins for serotypes 1-4.
Aalto has been leading the field in the development of the necessary diagnostic tools for ZIKV available to researchers in outbreak regions of Brazil, Columbia, Asia and the USA as well as to key scientific personnel in established infectious disease centers and pharmaceutical vaccine development centers worldwide.
‘With ZIKV now present in 60 plus countries across the globe and the most recent local transmission cases in Florida, what is most important is the accurate and fast diagnosis of the virus.’
The biggest challenge Aalto has seen to date in the serodiagnosis of ZIKV throughout 2016 is the confirmation of a true serology positive test for ZIKV in which the scientist has to rule out cross reactivity with DENV and or CHIKV. Aalto has developed the Tri-Plex of CHIKV-DENV-ZIKV proteins and antibodies through 2015 and 2016 in order for the diagnostic testers at the point of impact to be able to truly sero diagnose positive cases and rule out any cross reactivity with similar viruses carried by the Aedes ageypti mosquito.
"With ZIKV now present in 60 plus countries across the globe and the most recent local transmission cases in Florida, what is most important is the accurate and fast diagnosis of the virus. The Tri-Plex approach we have taken to diagnosing the virus with the launch of our CHIKV proteins in June of 2015, the launch of our ZIKV proteins in November of 2015, the launch of our ZIKV monoclonal antibodies in February 2016 and finally the launch of our DENV proteins in May of 2016 has allowed the leading disease scientists a complete tri testing suite of materials to accurately diagnose true ZIKV cases." Said Philip Noone, CEO of Aalto Bio Reagents.
"We are intent on not only challenging the earlier diagnosis of the virus but also challenging the mode of transmission to ensure all possible viruses that cross react with ZIKV are ruled out," added Noone.